<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Cadrenal Therapeutics, Inc. Common Stock — News on 6ix</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock</link>
<description>Latest news and press releases for Cadrenal Therapeutics, Inc. Common Stock on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 31 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/cadrenal-therapeutics-inc-common-stock" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68355af778dffbe2df0ebb2c.webp</url>
<title>Cadrenal Therapeutics, Inc. Common Stock</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock</link>
</image>
<item>
<title>Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-reports-fourth-quarter-2025-financial-results-provides-corporate-update-on-cad-1005-program-for-hit-following-end-of-phase-2-fda-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-reports-fourth-quarter-2025-financial-results-provides-corporate-update-on-cad-1005-program-for-hit-following-end-of-phase-2-fda-meeting</guid>
<pubDate>Tue, 31 Mar 2026 04:00:00 GMT</pubDate>
<description>Encouraging Phase 2 HIT data and recent FDA feedback support continued advancement of CAD-1005 as Cadrenal’s near-term development priority; broader 12-LOX</description>
</item>
<item>
<title>Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-highlights-research-supporting-12-lox-inhibition-in-reducing-inflammation-in-obesity-and-type-2-diabetes-7</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-highlights-research-supporting-12-lox-inhibition-in-reducing-inflammation-in-obesity-and-type-2-diabetes-7</guid>
<pubDate>Thu, 12 Mar 2026 04:00:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing innovative treatments</description>
</item>
<item>
<title>Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-highlights-recent-12-lox-inhibitor-platform-expansion</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-highlights-recent-12-lox-inhibitor-platform-expansion</guid>
<pubDate>Mon, 02 Mar 2026 05:00:00 GMT</pubDate>
<description>Encouraging data for CAD-1005 in Phase 2 HIT Study EOP2 scheduled for Q1 for top-priority indication Additional acute and chronic opportunities for 12-LOX</description>
</item>
<item>
<title>CVKD: Phase 2 HIT Results Show Encouraging Reduction in Thrombotic Events</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cvkd-phase-2-hit-results-show-encouraging-reduction-in-thrombotic-events</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cvkd-phase-2-hit-results-show-encouraging-reduction-in-thrombotic-events</guid>
<pubDate>Wed, 25 Feb 2026 11:38:00 GMT</pubDate>
<description>By David Bautz, PhD NASDAQ:CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Encouraging Results from Phase 2 HIT Trial On February 24, 2026, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced encouraging results from the Phase 2 trial of CAD-1005 (formerly CAD-1005) in heparin-induced thrombocytopenia (HIT). The results showed a meaningful reduction in thrombotic events despite not</description>
</item>
<item>
<title>Cadrenal Therapeutics Announces Phase 2 Results with Encouraging Reductions in Thrombotic Events for CAD-1005 in HIT, Supporting Clinical Advancement</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-announces-phase-2-results-with-encouraging-reductions-in-thrombotic-events-for-cad-1005-in-hit-supporting-clinical-advancement</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-announces-phase-2-results-with-encouraging-reductions-in-thrombotic-events-for-cad-1005-in-hit-supporting-clinical-advancement</guid>
<pubDate>Tue, 24 Feb 2026 13:30:00 GMT</pubDate>
<description>Greater than 25% absolute reduction in thrombotic events with CAD-1005 versus placebo on a background of standard anticoagulant therapy, despite no difference in platelet count recovery End-of-Phase 2 Meeting Scheduled for March 2026 PONTE VEDRA, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions, today announced encouraging results from a Phase</description>
</item>
<item>
<title>CVKD: Acquires 12-LOX Inhibitor for the Treatment of Heparin-Induced Thrombocytopenia (HIT)</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cvkd-acquires-12-lox-inhibitor-for-the-treatment-of-heparin-induced-thrombocytopenia-hit</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cvkd-acquires-12-lox-inhibitor-for-the-treatment-of-heparin-induced-thrombocytopenia-hit</guid>
<pubDate>Fri, 20 Feb 2026 11:05:00 GMT</pubDate>
<description>By David Bautz, PhD NASDAQ:CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Acquires 12-LOX Inhibitor VLX-1005 for the Treatment of HIT In December 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced the acquisition of VLX-1005 and related 12-lipoxygenase (12-LOX) assets from Veralox Therapeutics. VLX-1005 is a first-in-class, highly selective small molecule inhibitor of 12-LOX for</description>
</item>
<item>
<title>Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-highlights-high-incidence-130000725</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-highlights-high-incidence-130000725</guid>
<pubDate>Mon, 12 Jan 2026 13:00:00 GMT</pubDate>
<description>Company to also participate in Fireside Chat at Lytham Partners 2026 Investor Healthcare Summit on Thursday, January 15, 2026SAN FRANCISCO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today highlighted the significant and persistent unmet medical need in heparin-induced thrombocytopenia (HIT) and underscored the promise of its recent</description>
</item>
<item>
<title>Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhi...</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-highlights-high-incidence-of-thrombotic-complications-in-heparin-induced-thrombocytopenia-hit-at-the-jp-morgan-healthcare-conference-and-vlx-1005-as-a-potential-therapeutic-solution-as-the-first-and-only-selective-12-lox-inhi</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-highlights-high-incidence-of-thrombotic-complications-in-heparin-induced-thrombocytopenia-hit-at-the-jp-morgan-healthcare-conference-and-vlx-1005-as-a-potential-therapeutic-solution-as-the-first-and-only-selective-12-lox-inhi</guid>
<pubDate>Mon, 12 Jan 2026 05:00:00 GMT</pubDate>
<description>Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference</description>
</item>
<item>
<title>Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-conduct-partnering-investor-140000629</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-conduct-partnering-investor-140000629</guid>
<pubDate>Wed, 17 Dec 2025 14:00:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current anticoagulation therapy, today announced that members of its management team, including Quang X. Pham, CEO, will hold partnering and investor meetings during the 44th Annual J.P. Morgan Healthcare Conference, to be held January 12-15, 2026 in San Francisco, CA. “Attending the events surrounding t</description>
</item>
<item>
<title>Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-acquires-vlx-1005-130500103</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-acquires-vlx-1005-130500103</guid>
<pubDate>Thu, 11 Dec 2025 13:05:00 GMT</pubDate>
<description>Novel first-in-class therapeutic targeting a key immune signaling pathway and the underlying cause of HITIt is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds.Orphan Drug and Fast Track designations from the FDA PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of current a</description>
</item>
<item>
<title>Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-appoints-dr-lee-140000544</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-appoints-dr-lee-140000544</guid>
<pubDate>Mon, 01 Dec 2025 14:00:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced the appointment of Lee Scott Golden, M.D., to its Board of Directors, effective immediately. Dr. Golden will serve as an independent director. Dr. Golden currently serves as Executive Vice President and Chief Medical Officer at PTC Therapeutics, Inc. (Nasdaq: PTCT),</description>
</item>
<item>
<title>Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida’s Executive of the Year Award</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-ceo-quang-x-130000863</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-ceo-quang-x-130000863</guid>
<pubDate>Wed, 19 Nov 2025 13:00:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today announced its Chairman and Chief Executive Officer, Quang X. Pham, received the prestigious BioFlorida, Inc. “Executive of the Year Award,” at the recently held Florida Innovation Conference, powered by BioFlorida, in Orlando. As the voice of Florida’s life-science ecosystem,</description>
</item>
<item>
<title>Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-reports-third-quarter-140000243</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-reports-third-quarter-140000243</guid>
<pubDate>Mon, 10 Nov 2025 14:00:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome current gaps in anticoagulation therapy, today reported its financial results for the third quarter ended September 30, 2025, and provided an update on the clinical development of tecarfarin and the acquisition and development of frunexian. Highlights Progressed clinical development of tecarfarin. Completed the manufacturi</description>
</item>
<item>
<title>CVKD: Acquires Factor XIa Inhibitors…</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cvkd-acquires-factor-xia-inhibitors</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cvkd-acquires-factor-xia-inhibitors</guid>
<pubDate>Tue, 30 Sep 2025 11:05:00 GMT</pubDate>
<description>By David Bautz, PhD NASDAQ:CVKD READ THE FULL CVKD RESEARCH REPORT Business Update Acquires Portfolio of Factor XIa Inhibitors On September 15, 2025, Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) announced it had acquired a portfolio of Factor XIa inhibitors from eXIthera Pharmaceuticals. Included in the acquired assets is frunexian, a Phase 2-ready asset that is being developed as an acute</description>
</item>
<item>
<title>Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-participate-lytham-partners-203000921</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-participate-lytham-partners-203000921</guid>
<pubDate>Mon, 29 Sep 2025 20:30:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced that it will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2025 Investor Conference, taking place virtually on Tuesday, September 30, 2025. Company Webcast The webcast presentation will take place at 3:30 p</description>
</item>
<item>
<title>Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera’s Portfolio of Factor XIa Inhibitors</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-enhances-anticoagulation-pipeline-120000238</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-enhances-anticoagulation-pipeline-120000238</guid>
<pubDate>Mon, 15 Sep 2025 12:00:00 GMT</pubDate>
<description>Acquisition significantly enhances the Company’s pipeline by adding novel assets in acute and chronic anticoagulation settingsCompany is strategically poised to deliver differentiated therapeutics across the spectrum of cardiovascular thrombotic risk PONTE VEDRA, Fla., Sept. 15, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the gaps in anticoagulation therapy, today announced the acquisition of</description>
</item>
<item>
<title>Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-reports-second-quarter-120000504</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-reports-second-quarter-120000504</guid>
<pubDate>Mon, 11 Aug 2025 12:00:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., August 11, 2025--Cadrenal Therapeutics reports on Second Quarter 2025 financial results and provides corporate update on strategic clinical trial plans.</description>
</item>
<item>
<title>Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-announces-clinical-trial-100000134</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-announces-clinical-trial-100000134</guid>
<pubDate>Tue, 05 Aug 2025 10:00:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., August 05, 2025--Cadrenal announces clinical trial initiation plans for tecarfarin in patients with end-stage kidney disease (ESKD) who are transitioning to dialysis</description>
</item>
<item>
<title>Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-highlights-research-anticoagulation-120000058</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-highlights-research-anticoagulation-120000058</guid>
<pubDate>Thu, 12 Jun 2025 12:00:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., June 12, 2025--Cadrenal Therapeutics highlights new research on the economic and medical burden associated with oral anticoagulation for LVAD patients.</description>
</item>
<item>
<title>Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025</title>
<link>https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-engage-potential-partners-120000693</link>
<guid isPermaLink="true">https://6ix.com/company/cadrenal-therapeutics-inc-common-stock/news/cadrenal-therapeutics-engage-potential-partners-120000693</guid>
<pubDate>Wed, 04 Jun 2025 12:00:00 GMT</pubDate>
<description>PONTE VEDRA, Fla., June 04, 2025--Cadrenal Therapeutics will participate at this year's BIO International Convention 2025, taking place June 16-19, 2025 in Boston.</description>
</item>
</channel>
</rss>